InterCure Ltd. (NASDAQ:INCR – Get Free Report) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totaling 15,144 shares, a decline of 67.9% from the June 15th total of 47,234 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 104,980 shares, the short-interest ratio is currently 0.1 days.
InterCure Stock Up 4.2%
INCR stock traded up $0.04 during trading on Tuesday, reaching $0.99. The stock had a trading volume of 19,223 shares, compared to its average volume of 53,142. InterCure has a one year low of $0.68 and a one year high of $1.77. The company has a quick ratio of 0.97, a current ratio of 1.48 and a debt-to-equity ratio of 0.20. The company’s 50 day moving average is $0.96 and its two-hundred day moving average is $0.90. The company has a market capitalization of $54.13 million, a price-to-earnings ratio of 33.00 and a beta of 1.39.
InterCure (NASDAQ:INCR – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.10) EPS for the quarter. The business had revenue of $23.15 million for the quarter.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on InterCure
About InterCure
InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.
Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.
Further Reading
- Five stocks we like better than InterCure
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.
